Is Corcept Therapeutics Inc (CORT) a risky stock?
As of July 31, 2026, Clavix grades Corcept Therapeutics Inc (CORT) B- for risk, a composite score of 68 out of 100 on an A+ to F scale, which puts CORT in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 31, 2026. Clavix regrades every trading day.
The five risk dimensions behind CORT's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CORT scores on each, as of July 31, 2026.
What's moving CORT's risk right now
Company-specific signals Clavix flags behind CORT's current grade, drawn from recent news and filings as of July 31, 2026.
Corcept beat Q2 estimates with revenue up 32% to $256.1M, helped by strong Korlym sales and the early Lifyorli launch. The company raised its 2026 revenue outlook to $1.1-$1.2B.
Shares hit a new 52-week high and had their best day in nearly 16 months after strong Q2 results and a higher full-year outlook. Hedge fund Entropy Technologies disclosed a new 16,499-share position.
Recent CORT news
The latest headlines Clavix ingested for Corcept Therapeutics Inc, newest first. These feed the news-sentiment dimension of CORT's grade.
What a B- grade means
On the Clavix A+ to F scale, CORT's composite of 68 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CORT or any security. Grades are risk indicators, not predictions of return. Data may be delayed.